Ian T Clark
CIK 1336504 · Board of Director · last filed 2026-08-05
Ian T Clark is a Board of Director who has filed 136 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for GH, was dated Aug 5, 2026. Across all open-market trades the lifetime net is −$40.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.7M across reported positions. 3 SEC filings were submitted jointly with BIOMARIN PHARMACEUTICAL INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PALO ALTO, CA 94304
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GH | Director | 10,322 | $161.07 | $1.66M | -$20.42M | 51 | 2026-08-05 |
| OLMA | Director | 209,690 | $7.41 | $1.55M | -$7.87M | 9 | 2026-06-23 |
| CRVS | Director | — | $11.51 | — | $0 | 15 | 2026-06-15 |
| BMRN | Director | 14,490 | $57.16 | $828.3K | $0 | 2 | 2026-06-04 |
| KYTX | Director | 21,727 | $5.20 | $113.0K | $0 | 2 | 2026-05-29 |
| GDRX | Director | 100,150 | $3.60 | $360.0K | $0 | 3 | 2025-07-09 |
| Tectonic Therapeutic, Inc. (AVRO) Delisted | Director | — | $16.80 | — | $0 | 5 | 2023-06-08 |
| AGIO | Director | 6,549 | $31.31 | $205.0K | $0 | 8 | 2022-05-24 |
| Forty Seven, Inc. (FTSV) Delisted | Director | — | — | — | $0 | 2 | 2020-04-07 |
| Kite Pharma, Inc. (KITE) Delisted | Director | 7,100 | — | — | $0 | 2 | 2017-06-22 |
| TerraVia Holdings, Inc. (TVIA) Delisted | Director | — | — | — | $0 | 2 | 2017-05-23 |
| DNA | EVP-COMMERCIAL | 76 | $12.68 | $964 | -$11.81M | 14 | 2008-07-18 |
Recent Filings
136 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-05 | GH | Mixed | −5,092 | -$1.70M | EDGAR |
| 2026-08-04 | GH | Notice (144) | −14,180 | -$2.25M | EDGAR |
| 2026-06-23 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2026-06-22 | GH | Mixed | +5,092 | $0 | EDGAR |
| 2026-06-15 | CRVS | Grant (A) | — | $0 | EDGAR |
| 2026-06-04 | BMRN | Grant (A) | +7,490 | $0 | EDGAR |
| 2026-05-29 | KYTX | Grant (A) | +5,093 | $0 | EDGAR |
| 2026-05-22 | GH | Sell (S) | −6,876 | -$735.0K | EDGAR |
| 2026-05-20 | GH | Notice (144) | −6,876 | -$735.0K | EDGAR |
| 2026-05-13 | GDRX | Notice (144) | −43,100 | -$111.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.